Press release
Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"text","content":" PASADENA, Calif.--(BUSINESS WIRE)--\nArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:\n\nTIDES USA 2022: Oligonucleotide and Peptide Therapeutics – May 9-12, 2022\n\nTitle: Arrowhead’s Approach to Oligonucleotide Scale-Up Manufacturing\nPresenter: Michael Lawler, Director, Chemistry, Arrowhead Pharmaceuticals\n\n2022 American Thoracic Society (ATS) International Conference – May 13-18, 2022\n\nTitle: Silencing RAGE Expression with a Lung-Targeted RNAi Trigger Delivery Platform Suppresses Pulmonary Allergic Inflammation\nPresenter: David Kasahara, Senior Scientist III, Biology, Arrowhead Pharmaceuticals\n\nTitle: Silencing Muc5ac Expression with a Lung-Targeted RNAi Trigger Prevents Allergen-Induced Mucoobstruction and Airway Hyperresponsiveness\nPresenter: David Kasahara, Senior Scientist III, Biology, Arrowhead Pharmaceuticals\n\nBofA Securities 2022 Healthcare Conference – May 12, 2022, 1:40 p.m. ET\n\nType: Fireside chat presentation\nPresenter: Christopher Anzalone, President and CEO, Arrowhead Pharmaceuticals\n\n2022 RBC Capital Markets Global Healthcare Conference – May 17, 2022, 4:35 p.m. ET\n\nType: Fireside chat presentation\nPresenter: Christopher Anzalone, President and CEO, Arrowhead Pharmaceuticals\n\nUBS Global Healthcare Conference 2022 – May 25, 2022, 12:15 p.m. ET\n\nType: Fireside chat presentation\nPresenter: Vincent Anzalone, Vice President Finance and Investor Relations, Arrowhead Pharmaceuticals\n\nA copy of the presentation materials and webcast links may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.\n\nAbout Arrowhead Pharmaceuticals\n\nArrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.\n\nFor more information, please visit www.arrowheadpharma.com, or follow...